Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
Accent Therapeutics Announces $63 Million Series B Financing to Advance Novel, Precision Cancer Therapies Targeting RNA-Modifying Proteins
04/23/20, 11:31 AM
Location
lexingtonMoney raised
$63 million
Industry
biotechnology
Round Type
series b
Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced today that it has completed a $63 million Series B financing. The Series B was led by EcoR1 Capital with participation by GV, AbbVie Ventures, The Mark Foundation for Cancer Research, NS Investment and Droia Ventures as well as existing investors, Atlas Venture and The Column Group.
Company Info
Location
lexington, massachusetts, united states
Additional Info
Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.